|
1
|
Smith JJ and D'Angelica MI: Surgical
management of hepatic metastases of colorectal cancer. Hematol
Oncol Clin North Am. 29:61–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leporrier J, Maurel J, Chiche L, Bara S,
Segol P and Launoy G: A population-based study of the incidence,
management and prognosis of hepatic metastases from colorectal
cancer. Br J Surg. 93:465–474. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rees M, Tekkis PP, Welsh FK, O'Rourke T
and John TG: Evaluation of long-term survival after hepatic
resection for metastatic colorectal cancer: A multifactorial model
of 929 patients. Ann Surg. 247:125–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aloia TA, Vauthey JN, Loyer EM, Ribero D,
Pawlik TM, Wei SH, Curley SA, Zorzi D and Abdalla EK: Solitary
colorectal liver metastasis: Resection determines outcome. Arch
Surg. 141:460–467. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Simmonds PC, Primrose JN, Colquitt JL,
Garden OJ, Poston GJ and Rees M: Surgical resection of hepatic
metastases from colorectal cancer: A systematic review of published
studies. Br J Cancer. 94:982–999. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakai T, Ishikawa H, Tokoro T and Okuno K:
The clinical risk score predicts the effectiveness of adjuvant
chemotherapy for colorectal liver metastasis. World J Surg.
39:1527–1536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kanas GP, Taylor A, Primrose JN, Langeberg
WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA and Poston G:
Survival after liver resection in metastatic colorectal cancer:
Review and meta-analysis of prognostic factors. Clin Epidemiol.
4:283–301. 2012.PubMed/NCBI
|
|
8
|
Petrelli NJ: Perioperative or adjuvant
therapy for resectable colorectal hepatic metastases. J Clin Oncol.
26:4862–4863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fong Y, Fortner J, Sun RL, Brennan MF and
Blumgart LH: Clinical score for predicting recurrence after hepatic
resection for metastatic colorectal cancer: Analysis of 1001
consecutive cases. Ann Surg. 230:309–321. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rahbari NN, Reissfelder C,
Schulze-Bergkamen H, Jäger D, Büchler MW, Weitz J and Koch M:
Adjuvant therapy after resection of colorectal liver metastases:
The predictive value of the MSKCC clinical risk score in the era of
modern chemotherapy. BMC Cancer. 14:1742014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mann CD, Metcalfe MS, Leopardi LN and
Maddern GJ: The clinical risk score: Emerging as a reliable
preoperative prognostic index in hepatectomy for colorectal
metastases. Arch Surg. 139:1168–1172. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ayez N, van der Stok EP, Grunhagen DJ,
Rothbarth J, van Meerten E, Eggermont AM and Verhoef C: The use of
neo-adjuvant chemotherapy in patients with resectable colorectal
liver metastases: Clinical risk score as possible discriminator.
Eur J Surg Oncol. 41:859–867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reddy SK, Kattan MW, Yu C, Ceppa EP, de la
Fuente SG, Fong Y, Clary BM and White RR: Evaluation of
peri-operative chemotherapy using a prognostic nomogram for
survival after resection of colorectal liver metastases. HPB
(Oxford). 11:592–599. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar R, Dennison AR, Robertson V, Jones
MJ, Neal CP and Garcea G: Clinical risk scores in the current era
of neoadjuvant chemotherapy for colorectal liver metastases. ANZ J
Surg. Sep 12–2016.(Epub ahead of print). View Article : Google Scholar
|
|
15
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative FOLFOX4 chemotherapy and
surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC 40983): Long-term results of a randomised,
controlled, phase 3 trial. Lancet Oncol. 14:1208–1215. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baize N, Gerard B, Bleiberg H, Caroli-Bosc
F, Berthier F, Legendre H, Pector JC and Hendlisz A: Long-term
survival of patients downstaged by oxaliplatin and 5-fluorouracil
combination followed by rescue surgery for unresectable colorectal
liver metastases. Gastroenterol Clin Biol. 30:1349–1353. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adam R, Delvart V, Pascal G, Valeanu A,
Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F,
Ghémard O, et al: Rescue surgery for unresectable colorectal liver
metastases downstaged by chemotherapy: A model to predict long-term
survival. Ann Surg. 240:644–658. 2004.PubMed/NCBI
|
|
18
|
Vessie EL, Liu DM, Forster B, Kos S,
Baxter K, Gagnon J and Klass D: A practical guide to magnetic
resonance vascular imaging: Techniques and applications. Ann Vasc
Surg. 28:1052–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Allen PJ, Kemeny N, Jarnagin W, DeMatteo
R, Blumgart L and Fong Y: Importance of response to neoadjuvant
chemotherapy in patients undergoing resection of synchronous
colorectal liver metastases. J Gastrointest Surg. 7:109–117. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vigano L, Capussotti L, Barroso E, Nuzzo
G, Laurent C, Ijzermans JN, Gigot JF, Figueras J, Gruenberger T,
Mirza DF, et al: Progression while receiving preoperative
chemotherapy should not be an absolute contraindication to liver
resection for colorectal metastases. Ann Surg Oncol. 19:2786–2796.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumors:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zendel A, Lahat E, Dreznik Y, Zakai BB,
Eshkenazy R and Ariche A: ‘Vanishing liver metastases’-A real
challenge for liver surgeons. Hepatobiliary Surg Nutr. 3:295–302.
2014.PubMed/NCBI
|
|
23
|
Jones RP, Stattner S, Sutton P, Dunne DF,
McWhirter D, Fenwick SW, Malik HZ and Poston GJ: Controversies in
the oncosurgical management of liver limited stage IV colorectal
cancer. Surg Oncol. 23:53–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clavien PA, Petrowsky H, DeOliveira ML and
Graf R: Strategies for safer liver surgery and partial liver
transplantation. N Engl J Med. 356:1545–1559. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ruers T, Punt C, Van Coevorden F, Pierie
JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA,
Mauer M, et al: Radiofrequency ablation combined with systemic
treatment versus systemic treatment alone in patients with
non-resectable colorectal liver metastases: A randomized EORTC
Intergroup phase II study (EORTC 40004). Ann Oncol. 23:2619–2626.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanis E, Nordlinger B, Mauer M, Sorbye H,
van Coevorden F, Gruenberger T, Schlag PM, Punt CJ, Ledermann J and
Ruers TJ: Local recurrence rates after radiofrequency ablation or
resection of colorectal liver metastases. Analysis of the European
Organisation for Research and Treatment of Cancer #40004 and
#40983. Eur J Cancer. 50:912–919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Adam R, Pascal G, Castaing D, Azoulay D,
Delvart V, Paule B, Levi F and Bismuth H: Tumor progression while
on chemotherapy: A contraindication to liver resection for multiple
colorectal metastases? Ann Surg. 240:1052–1064. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Neumann UP, Thelen A, Röcken C, Seehofer
D, Bahra M, Riess H, Jonas S, Schmeding M, Pratschke J, Bova R and
Neuhaus P: Nonresponse to pre-operative chemotherapy does not
preclude long-term survival after liver resection in patients with
colorectal liver metastases. Surgery. 146:52–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gallagher DJ, Zheng J, Capanu M, Haviland
D, Paty P, Dematteo RP, D'Angelica M, Fong Y, Jarnagin WR, Allen PJ
and Kemeny N: Response to neoadjuvant chemotherapy does not predict
overall survival for patients with synchronous colorectal hepatic
metastases. Ann Surg Oncol. 16:1844–1851. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Adam R, De Gramont A, Figueras J, Guthrie
A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P,
Rubbia-Brandt L, et al: The oncosurgery approach to managing liver
metastases from colorectal cancer: A multidisciplinary
international consensus. Oncologist. 17:1225–1239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai
SY, Ye QH, Yu Y, Xu B, Qin XY and Xu J: Randomized controlled trial
of cetuximab plus chemotherapy for patients with KRAS wild-type
unresectable colorectal liver-limited metastases. J Clin Oncol.
31:1931–1938. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Levi FA, Boige V, Hebbar M, Smith D,
Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, et
al: Conversion to resection of liver metastases from colorectal
cancer with hepatic artery infusion of combined chemotherapy and
systemic cetuximab in multicenter trial OPTILIV. Ann Oncol.
27:267–274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Roock W, Piessevaux H, De Schutter J,
Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL,
Peeters M, Humblet Y, et al: KRAS wild-type state predicts survival
and is associated to early radiological response in metastatic
colorectal cancer treated with cetuximab. Ann Oncol. 19:508–515.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roth AD, Tejpar S, Delorenzi M, Yan P,
Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C,
et al: Prognostic role of KRAS and BRAF in stage II and III
resected colon cancer: Results of the translational study on the
PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol. 28:466–474.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
